Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients

Journal of Viral Hepatitis

Volumn 16, Issue 6, 2009, Pages 388-396

  Wada, M ^b   Marusawa, H ^a,b   Yamada, R ^a   Nasu, A ^b   Osaki, Y ^c   Kudo, M ^d   Nabeshima, M ^e   Fukuda, Y ^a   Chiba, T ^b   Matsuda, F ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Department of Gastroenterology and Hepatology ^*  (Japan)

^c OSAKA RED CROSS HOSPITAL   (Japan)

^d KINKI UNIVERSITY   (Japan)

^e KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

Author keywords

Haematologic adverse effect; Hepatitis C; Interferon; Single nucleotide polymorphism; Sustained virologic response

Indexed keywords

PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ABDOMINAL DISCOMFORT; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CHRONIC HEPATITIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; EXON; FEMALE; GENE LOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; JAPANESE; LEUKOPENIA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; NEUTROPENIA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON REGULATORY FACTOR-7; INTERFERONS; JAPAN; MALE; MIDDLE AGED; NEUTROPENIA; POINT MUTATION; POLYMORPHISM, GENETIC; RECEPTOR, INTERFERON ALPHA-BETA; RNA, VIRAL; STAT2 TRANSCRIPTION FACTOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65449175293     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01095.x     Document Type: Article

References (43)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001 345 : 41 52. (Pubitemid 32634271)
2. National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002 36 : S3 20.
3. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006 130 : 231 264 quiz 214-237. (Pubitemid 43049856)
4. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006 355 : 2444 2451.
5. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
6. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965. (Pubitemid 32913521)
7. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355. (Pubitemid 38268915)
8. Matsuyama N, Mishiro S, Sugimoto M et al. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 2003 25 : 221 225. (Pubitemid 36546347)
9. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999 30 : 526 530. (Pubitemid 29357520)
10. Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001 33 : 708 712. (Pubitemid 32185234)
11. Dai CY, Chuang WL, Chang WY et al. Tumor necrosis factor-alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection. J Infect Dis 2006 193 : 98 101. (Pubitemid 43032504)
12. Huang Y, Yang H, Borg BB et al. A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci U S A 2007 104 : 985 990. (Pubitemid 46154723)
13. Promrat K, McDermott DH, Gonzalez CM et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 2003 124 : 352 360. (Pubitemid 36169252)
14. Naito M, Matsui A, Inao M et al. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J Gastroenterol 2005 40 : 381 388. (Pubitemid 40723929)
15. Schott E, Witt H, Neumann K et al. Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy. J Viral Hepatol 2008 15 : 71 78. (Pubitemid 350243584)
16. Wasmuth HE, Werth A, Mueller T et al. Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C. Hepatology 2004 40 : 327 334. (Pubitemid 39062850)
17. Bonkovsky HL, Naishadham D, Lambrecht RW et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006 131 : 1440 1451.
18. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 : 1485 1492. (Pubitemid 28543497)
19. Borden EC, Sen GC, Uze G et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007 6 : 975 990. (Pubitemid 350201788)
20. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004 39 : 880 890. (Pubitemid 38428923)
21. de Veer MJ, Holko M, Frevel M et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 2001 69 : 912 920. (Pubitemid 32577892)
22. Gale M Jr., Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005 436 : 939 945. (Pubitemid 41191669)
23. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006 7 : 131 137. (Pubitemid 43135878)
24. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006 6 : 644 658. (Pubitemid 44298214)
25. Stellacci E, Testa U, Petrucci E et al. Interferon regulatory factor-2 drives megakaryocytic differentiation. Biochem J 2004 377 : 367 378. (Pubitemid 38142192)
26. Mizutani T, Tsuji K, Ebihara Y et al. Homeostatic erythropoiesis by the transcription factor IRF2 through attenuation of type I interferon signaling. Exp Hematol 2008 36 : 255 264.
27. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994 20 : 15 20. (Pubitemid 24196485)
28. Takahashi M, Matsuda F, Margetic N, Lathrop M. Automated identification of single nucleotide polymorphisms from sequencing data. J Bioinform Comput Biol 2003 1 : 253 265.
29. Sebastiani P, Lazarus R, Weiss ST, Kunkel LM, Kohane IS, Ramoni MF. Minimal haplotype tagging. Proc Natl Acad Sci U S A 2003 100 : 9900 9905. (Pubitemid 37087040)
30. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002 36 : S237 S244. (Pubitemid 35253486)
31. Matthews SJ, McCoy C. Peginterferon alfa-2a: a review of approved and investigational uses. Clin Ther 2004 26 : 991 1025. (Pubitemid 39141804)
32. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006 55 : 1350 1359. (Pubitemid 44277369)
33. Ernstoff MS, Kirkwood JM. Changes in the bone marrow of cancer patients treated with recombinant interferon alpha-2. Am J Med 1984 76 : 593 596. (Pubitemid 14127548)
34. Ganser A, Carlo-Stella C, Greher J, Volkers B, Hoelzer D. Effect of recombinant interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 1987 70 : 1173 1179. (Pubitemid 18022400)
35. Peck-Radosavljevic M, Wichlas M, Pidlich J et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998 28 : 1424 1429. (Pubitemid 28493856)
36. Dormann H, Krebs S, Muth-Selbach U et al. Rapid onset of hematotoxic effects after interferon alpha in hepatitis C. J Hepatol 2000 32 : 1041 1042. (Pubitemid 30368102)
37. Mason KD, Carpinelli MR, Fletcher JI et al. Programmed anuclear cell death delimits platelet life span. Cell 2007 128 : 1173 1186. (Pubitemid 46427871)
38. Chawla-Sarkar M, Lindner DJ, Liu YF et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003 8 : 237 249. (Pubitemid 36749609)
39. Kimchi-Sarfaty C, Oh JM, Kim IW et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007 315 : 525 528. (Pubitemid 46175758)
40. Lehman TA, Haffty BG, Carbone CJ et al. Elevated frequency and functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res 2000 60 : 1062 1069. (Pubitemid 30129546)
41. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000 132 : 296 305. (Pubitemid 30106261)
42. Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat 2000 7 : 250 257.
43. Tsubota A, Chayama K, Ikeda K et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994 19 : 1088 1094. (Pubitemid 24134229)